Granted Patent
B2
US 12,590,169 · App. 17/283,830 · Granted Mar 31, 2026
5T4 single domain antibodies and therapeutic compositions thereof
Inventors:
John C. Timmer (La Jolla, CA); Michael D. Kaplan (La Jolla, CA); Katelyn M. Willis (La Jolla, CA); Rajay A. Pandit (La Jolla, CA); Angelica N. Sanabria (La Jolla, CA); Sydney A. Barnes (La Jolla, CA); Margaret E. Haerr (La Jolla, CA); Brendan P. Eckelman (La Jolla, CA); Rutger H. Jackson (La Jolla, CA)
Assignee:
Inhibrx Biosciences, Inc.
C07K16/30A61P35/00C07K14/56C07K14/565C07K14/57C07K16/2809C07K16/2818C07K16/283C07K2317/21C07K2317/24C07K2317/31C07K2317/33C07K2317/35C07K2317/565C07K2317/569C07K2317/624C07K2317/71C07K2317/72C07K2317/76C07K2317/92C07K2319/00C07K2319/50
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are binding polypeptides that specifically bind 5T4. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind 5T4. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided 5T4 binding polypeptides for treating diseases and conditions, such as cancer.
Claims (29)
1 . A 5T4-binding polypeptide construct, comprising at least one heavy chain only variable domain (5T4 VHH domain) comprising a complementarity determining region 1 (CDR1) comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 86-87 and 288-292, 296, and 297; a complementarity determining region 2 (CDR2) comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 88-99, 298, and 299; and a complementarity determining region 3 (CDR3) comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 100-102, 300, 301, and 303.
2 . The 5T4-binding polypeptide construct of claim 1 , wherein the at least one 5T4 VHH domain is humanized.
3 . The 5T4-binding polypeptide construct of claim 1 , wherein the polypeptide construct comprises an immunoglobulin Fc region.
4 . The 5T4-binding polypeptide construct of claim 1 that is a dimer.
5 . The 5T4-binding polypeptide construct of claim 3 , wherein the Fc region is a heterodimeric Fc region.
6 . The 5T4-binding polypeptide construct of claim 1 , wherein the at least one 5T4 VHH domain comprises (i) the sequence set forth in SEQ ID NO: 245, (ii) a humanized variant of SEQ ID NO:245, or (iii) a sequence of amino acids that exhibits at least 85% sequence identity to SEQ ID NO:245 and binds 5T4.
7 . The 5T4-binding polypeptide construct of claim 1 , wherein
the at least one 5T4 VHH domain comprises a CDR1, CDR2 and CDR3 set forth in SEQ ID NOS: 288, 88, and 100, respectively; or SEQ ID NOS: 289, 88, and 100, respectively.
8 . The 5T4-binding polypeptide construct of claim 1 , wherein the at least one 5T4 VHH domain comprises the sequence of amino acids set forth in any one of SEQ ID NOs: 246-253 and 360 or a sequence of amino acids that exhibits at least 85% sequence identity to any of SEQ ID NO: 246-253 and 360 and binds 5T4.
9 . The 5T4-binding polypeptide construct of claim 1 , wherein the at least one 5T4 VHH domain comprises (i) the sequence set forth in SEQ ID NO: 255, (ii) a humanized variant of SEQ ID NO: 255, or (iii) a sequence of amino acids that exhibits at least 85% sequence identity to SEQ ID NO: 255 and binds 5T4.
10 . The 5T4-binding polypeptide construct of claim 1 , wherein
the at least one 5T4 VHH domain comprises a CDR1 comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 86, 290-292; a CDR2 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 89-94; and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 101.
11 . The 5T4-binding polypeptide construct of claim 1 , wherein the at least one 5T4 VHH domain comprises the sequence of amino acids set forth in any one of SEQ ID NOs: 256-275 or a sequence of amino acids that exhibits at least 85% sequence identity to any of SEQ ID NO: 256-275 and binds 5T4.
12 . The 5T4-binding polypeptide construct of claim 1 , wherein the at least one 5T4 VHH domain comprises (i) the sequence set forth in SEQ ID NO: 276, (ii) a humanized variant of SEQ ID NO: 276, or (iii) a sequence of amino acids that exhibits at least 85% sequence identity to SEQ ID NO: 276 and binds 5T4.
13 . The 5T4-binding polypeptide construct of claim 1 , wherein
the at least one 5T4 VHH domain comprises a CDR1 comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 86 and 87; a CDR2 comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 95-99; and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 102.
14 . The 5T4-binding polypeptide construct of claim 1 , wherein the at least one 5T4 VHH domain comprises the sequence of amino acids set forth in any one of SEQ ID NOs: 277-287 or a sequence of amino acids that exhibits at least 85% sequence identity to any one of SEQ ID NO: 277-287 and binds 5T4.
15 . The 5T4-binding polypeptide construct of claim 1 , wherein
the at least one 5T4 VHH domain comprises (i) the sequence set forth in SEQ ID NO: 294, 295, or 302, (ii) a humanized variant of SEQ ID NO: 294, 295, or 302, or (iii) a sequence of amino acids that exhibits at least 85% sequence identity to SEQ ID NO: 294, 295, or 302 and binds 5T4.
16 . The 5T4-binding polypeptide construct of claim 1 , wherein the 5T4-binding polypeptide construct comprises a first 5T4 VHH domain that specifically binds 5T4 and a second 5T4 VHH domain that specifically binds 5T4, wherein the first and second 5T4 VHH domains comprise the CDR1 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 86-87 and 288-292, 296, and 297; the CDR2 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 88-99, 298, and 299; and the CDR3 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 100-102, 300, 301, and 303.
17 . The 5T4-binding polypeptide construct of claim 16 , wherein:
the first 5T4 VHH domain comprises the amino acid sequence set forth in any one of SEQ ID NOS: 245-253, 295, 302, and 360, a humanized variant thereof, or a sequence of amino acids that exhibits at least 85% sequence identity to any of SEQ ID NOS: 245-253, 295, 302, and 360, and binds 5T4; and
the second 5T4 VHH domain comprises the amino acid sequence set forth in any one of SEQ ID NOS: 255-287, 294, 302, a humanized variant thereof, or a sequence of amino acids that exhibits at least 85% sequence identity to any of SEQ ID NOS: 255-287, 294, 302, and binds 5T4.
18 . The 5T4-binding polypeptide construct of claim 1 , wherein the at least one 5T4 VHH domain comprises a CDR1, CDR2 and CDR3 set forth in SEQ ID NOS: 290, 90, and 101, respectively; SEQ ID NOS: 290, 91, and 101, respectively; SEQ ID NOS: 290, 92, and 101, respectively; SEQ ID NOS: 290, 93, and 101, respectively; SEQ ID NOS: 290, 94, and 101, respectively; SEQ ID NOS: 291, 94, and 101, respectively; SEQ ID NOS: 292, 94, and 101, respectively; or SEQ ID NOS: 86, 94, and 101, respectively.
19 . The 5T4-binding polypeptide construct of claim 1 , wherein the at least one 5T4 VHH domain comprises a CDR1, CDR2 and CDR3 set forth in SEQ ID NOS: 87, 95, and 102, respectively; SEQ ID NOS: 87, 96, and 102, respectively; SEQ ID NOS: 87, 97, and 102, respectively; SEQ ID NOS: 87, 98, and 102, respectively; SEQ ID NOS: 87, 99, and 102, respectively; or SEQ ID NOS: 86, 98, and 102, respectively.
20 . The 5T4-binding polypeptide construct of claim 1 , wherein the at least one 5T4 VHH domain comprises a CDR1 comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 288, 296, or 297; a CDR2 comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 88, 298, or 299; and a CDR3 comprising the amino acid sequence selected from the group consisting of SEQ ID NO:300, 301, or 303.
21 . An isolated single domain antibody (sdAb) that binds 5T4, comprising a complementarity determining region 1 (CDR1) comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 86-87 and 288-292, 296, and 297; a complementarity determining region 2 (CDR2) comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 88-99, 298, and 299; and a complementarity determining region 3 (CDR3) comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 100-102, 300, 301, and 303.
22 . The isolated single domain antibody of claim 21 , comprising the amino acid sequence set forth in any of SEQ ID NOS: 245-253, 255-287, 294, 295, 302, and 360, or a sequence of amino acids that exhibits at least 85% sequence identity to any of SEQ ID NOS: 245-253, 255-287, 294, 295, 302, and 360, and binds 5T4.
23 . A pharmaceutical composition comprising the 5T4-binding polypeptide construct of claim 1 .
Assignments (5)
SECURITY INTEREST
Recorded Jan 14, 2025
From: INHIBRX BIOSCIENCES, INC.
To: OXFORD FINANCE LLC; OXFORD FINANCE LLC
Reel/Frame 069894/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 10, 2024
From: INHIBRX, INC.
To: INHIBRX BIOSCIENCES, INC.
Reel/Frame 067679/0635 →
RELEASE OF SECURITY INTEREST
Recorded Jun 3, 2024
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: INHIBRX, INC.
Reel/Frame 067606/0247 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT
Recorded Feb 28, 2022
From: INHIBRX, INC.
To: OXFORD FINANCE LLC
Reel/Frame 059262/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 5, 2021
From: TIMMER, JOHN C.; KAPLAN, MICHAEL D.; WILLIS, KATELYN M.; PANDIT, RAJAY A.; SANABRIA, ANGELICA N.; BARNES, SYDNEY A.; HAERR, MARGARET E.; ECKELMAN, BRENDAN P.; JACKSON, RUTGER H.
To: INHIBRX, INC.
Reel/Frame 057097/0600 →
Continuity (3)
Provisional Application
62877824
· Jul 23, 2019
Provisional Application
62744631
· Oct 11, 2018
References Cited (355)
US 4522811A
· Eppstein et al.
· 1985
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 4832959A
· Engels et al.
· 1989
[cited by applicant]
US 5258498A
· Huston et al.
· 1993
[cited by applicant]
US 5500362A
· Robinson et al.
· 1996
[cited by applicant]
US 5525491A
· Huston et al.
· 1996
[cited by applicant]
US 5731168A
· Carter et al.
· 1998
[cited by applicant]
US 5821337A
· Carter et al.
· 1998
[cited by applicant]
US 5834597A
· Tso et al.
· 1998
[cited by applicant]
US 6054297A
· Carter et al.
· 2000
[cited by applicant]
US 6120762A
· Johnson et al.
· 2000
[cited by applicant]
US 6132992A
· Ledbetter et al.
· 2000
[cited by applicant]
US 6982321B2
· Winter
· 2006
[cited by applicant]
US 7087409B2
· Barbas et al.
· 2006
[cited by applicant]
US 7183076B2
· Arathoon et al.
· 2007
[cited by applicant]
US 7381803B1
· Weiner et al.
· 2008
[cited by applicant]
US 7527791B2
· Adams et al.
· 2009
[cited by applicant]
US 7635475B2
· Kumagai et al.
· 2009
[cited by applicant]
US 7728114B2
· Mach et al.
· 2010
[cited by applicant]
US 7959925B2
· Weinberg et al.
· 2011
[cited by applicant]
US 7994289B2
· Waldmann et al.
· 2011
[cited by applicant]
US 7998469B2
· Gantier et al.
· 2011
[cited by applicant]
US 8052964B2
· Gantier et al.
· 2011
[cited by applicant]
US 9006399B2
· Liu et al.
· 2015
[cited by applicant]
US 9035026B2
· Hoffmann et al.
· 2015
[cited by applicant]
US 9605084B2
· Moore et al.
· 2017
[cited by applicant]
US 9644016B2
· Stagliano et al.
· 2017
[cited by applicant]
US 9650446B2
· Moore et al.
· 2017
[cited by applicant]
US 9701750B2
· Hoffmann et al.
· 2017
[cited by applicant]
US 9701759B2
· Desjarlais et al.
· 2017
[cited by applicant]
US 9803021B2
· Morrison
· 2017
[cited by applicant]
US 20080279851A1
· Coyle et al.
· 2008
[cited by applicant]
US 20100254998A1
· Bossenmaier et al.
· 2010
[cited by applicant]
US 20130273054A1
· Bossenmaier et al.
· 2013
[cited by applicant]
US 20140072581A1
· Dixit et al.
· 2014
[cited by applicant]
US 20140154253A1
· Ng et al.
· 2014
[cited by applicant]
US 20150087810A1
· Moore et al.
· 2015
[cited by applicant]
US 20150239991A1
· Blein et al.
· 2015
[cited by applicant]
US 20160280795A1
· Wang
· 2016
[cited by applicant]
US 20180355038A1
· Smith et al.
· 2018
[cited by applicant]
US 20190218515A1
· Ballesteros Nobell et al.
· 2019
[cited by applicant]
US 20190330366A1
· Eckelman et al.
· 2019
[cited by applicant]
US 20240101704A1
· Eckelman et al.
· 2024
[cited by applicant]
CA 2477192
· 2001
[cited by applicant]
CA 2441653
· 2005
[cited by applicant]
CN 101583376
· 2009
[cited by applicant]
CN 108084265
· 2018
[cited by applicant]
EP 0219781
· 1987
[cited by applicant]
EP 1391213
· 2004
[cited by applicant]
EP 2920209
· 2015
[cited by applicant]
EP 3502140
· 2019
[cited by applicant]
WO WO1992008737
· 1992
[cited by applicant]
WO WO1994004679
· 1994
[cited by applicant]
WO WO1998050431
· 1998
[cited by applicant]
WO WO2000024884
· 2000
[cited by applicant]
WO WO2000041474
· 2000
[cited by applicant]
WO WO2002059264
· 2002
[cited by applicant]
WO WO2002079249
· 2002
[cited by applicant]
WO WO2002083733
· 2002
[cited by applicant]
WO WO2002086156
· 2002
[cited by applicant]
WO WO2002095067
· 2002
[cited by applicant]
WO WO2002101048
· 2002
[cited by applicant]
WO WO2003000896
· 2003
[cited by applicant]
WO WO2003023032
· 2003
[cited by applicant]
WO WO2004022593
· 2004
[cited by applicant]
WO WO2004022747
· 2004
[cited by applicant]
WO WO2004092219
· 2004
[cited by applicant]
WO WO2005035584
· 2005
[cited by applicant]
WO WO2005040220
· 2005
[cited by applicant]
WO WO2005063816
· 2005
[cited by applicant]
WO WO2005100402
· 2005
[cited by applicant]
WO WO2006029879
· 2006
[cited by applicant]
WO WO2007033230
· 2007
[cited by applicant]
WO WO2008119567
· 2008
[cited by applicant]
WO WO2009018386
· 2009
[cited by applicant]
WO WO2009067800
· 2009
[cited by applicant]
WO WO2009089004
· 2009
[cited by applicant]
WO WO2010037836
· 2010
[cited by applicant]
WO WO2010151792
· 2010
[cited by applicant]
WO WO2011056983
· 2011
[cited by applicant]
WO WO2011133886
· 2011
[cited by applicant]
WO WO2011143545
· 2011
[cited by applicant]
WO WO2012025525
· 2012
[cited by applicant]
WO WO2012058768
· 2012
[cited by applicant]
WO WO2013026837
· 2013
[cited by applicant]
WO WO2013041687
· 2013
[cited by applicant]
WO WO2013101909
· 2013
[cited by applicant]
WO WO2013128194
· 2013
[cited by applicant]
WO WO2014067011
· 2014
[cited by applicant]
WO WO2014099997
· 2014
[cited by applicant]
WO WO2014145806
· 2014
[cited by applicant]
WO WO2014194100
· 2014
[cited by applicant]
WO WO2015001085
· 2015
[cited by applicant]
WO WO2015026894
· 2015
[cited by applicant]
WO WO2015168469
· 2015
[cited by applicant]
WO WO2015187793
· 2015
[cited by applicant]
WO WO2015197598
· 2015
[cited by applicant]
WO WO2015197789
· 2015
[cited by applicant]
WO WO2016020309
· 2016
[cited by applicant]
WO WO2016034666
· 2016
[cited by applicant]
WO WO2016046778
· 2016
[cited by applicant]
WO WO2016055593
· 2016
[cited by applicant]
WO WO2015095392
· 2016
[cited by applicant]
WO WO2016086189
· 2016
[cited by applicant]
WO WO2016087416
· 2016
[cited by applicant]
WO WO2016097408
· 2016
[cited by applicant]
WO WO2016105450
· 2016
[cited by applicant]
WO WO2016097408A1
· 2016
[cited by examiner]
WO WO2016177762
· 2016
[cited by applicant]
WO WO2016179517
· 2016
[cited by applicant]
WO WO2016180982
· 2016
[cited by applicant]
WO WO2016204966
· 2016
[cited by applicant]
WO WO2017015623
· 2017
[cited by applicant]
WO WO2017055398
· 2017
[cited by applicant]
WO WO2017060144
· 2017
[cited by applicant]
WO WO2017123650
· 2017
[cited by applicant]
WO WO2017123673
· 2017
[cited by applicant]
WO WO2017134440
· 2017
[cited by applicant]
WO WO2017167672
· 2017
[cited by applicant]
WO WO2017182672
· 2017
[cited by applicant]
WO WO2018027025
· 2018
[cited by applicant]
WO WO2018068695
· 2018
[cited by applicant]
WO WO2018127473
· 2018
[cited by applicant]
WO WO2018167486
· 2018
[cited by applicant]
WO WO2018185045
· 2018
[cited by applicant]
WO WO2018191438
· 2018
[cited by applicant]
WO WO2018191438A1
· 2018
[cited by examiner]
WO WO2019133761
· 2019
[cited by applicant]
WO WO2019200022
· 2019
[cited by applicant]
WO WO2020023553
· 2020
[cited by applicant]
WO WO2020023553A1
· 2020
[cited by examiner]
WO WO2020076970
· 2020
[cited by applicant]
WO WO2020076977
· 2020
[cited by applicant]
WO WO2021155071
· 2021
[cited by applicant]
Skolnick et al (Trends Biotechnol. Jan. 2000;18(1):34-9) (Year: 2000).
[cited by examiner]
Burgess et al. (J. Cell Biol. 111:2129-2138, 1990) (Year: 1990).
[cited by examiner]
Miosge (Proc Natl Acad Sci U S A. Sep. 15, 2015;112(37):E5189-98) (Year: 2015).
[cited by examiner]
Bork (Genome Research, 2000,10:398-400) (Year: 2000).
[cited by examiner]
Kulmanov et al (Bioinformatics, 34(4), 2018, 660-668) (Year: 2018).
[cited by examiner]
Vajdos et al. (J Mol Biol. Jul. 5, 2002;320(2):415-28) (Year: 2002).
[cited by examiner]
Brown et al. (J Immunol. May 1996;156(9):3285-91) (Year: 1996).
[cited by examiner]
Vattekatte, (PeerJ. Mar. 6, 2020:8:e8408. doi: 10.7717/peerj.8408. eCollection 2020.) (Year: 2020).
[cited by examiner]
Lloyd et al. (Protein Eng Des Sel. Mar. 2009;22(3):159-68. Epub Oct. 29, 2008.) (Year: 2009).
[cited by examiner]
Goel et al. (J Immunol. Dec. 15, 2004;173(12):7358-67) (Year: 2004).
[cited by examiner]
Khan et al. (J Immunol (2014) 192 (11): 5398-5405) (Year: 2014).
[cited by examiner]
Poosarla et al. (Biotechnol Bioeng. Jun. 2017 ; 114(6): 1331-1342) (Year: 2017).
[cited by examiner]
Rabia, et al. (Biochem Eng J. Sep. 15, 2018:137:365-374. Epub Jun. 5, 2018) (Year: 2018).
[cited by examiner]
Asano et al. “Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody.”
[cited by applicant]
Barthelemy et al. “Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains.”
[cited by applicant]
Beiboer et al. “Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.”
[cited by applicant]
Choi et al. “Predicting antibody complementarity determining region structures without classification.”
[cited by applicant]
De Genst et al. “Antibody repertoire development in camelids.”
[cited by applicant]
Driessens et al. “Costimulatory and coinhibitory receptors in anti-tumor immunity.”
[cited by applicant]
Griffiths et al. “Human anti-self antibodies with high specificity from phage display libraries.”
[cited by applicant]
Kuo et al., “Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells,” Protein Eng Des Sel. (2012) 25(10): 561-9.
[cited by applicant]
Maeda et al., “Engineering of functional chimeric protein G-Vargula luciferase,” Anal Biochem. (1997) 249(2):147-52.
[cited by applicant]
Malia et al. “Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8.”
[cited by applicant]
Schmiedel e tal. “Expression of a bispecific dsFv-dsFv′ antibody fragment in
[cited by applicant]
Weidle et al. “The intriguing options of multispecific antibody formats for treatment of cancer.”
[cited by applicant]
Xing et al., “BiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells,” Transl Oncol (2017) 10(5):780-785.
[cited by applicant]
Zhang et al., “Amplification Ex Vivo and Cytocidal Activity of Leukemia Tumor-Associated Antigen-Specific Cytotoic T Lympohcytes,” Chinese Journal of Experimental Hematology, (2015) 23(3); 814-820; (Article in Chinese; …
[cited by applicant]
Kumar et al., “Molecular cloning and expression of the Fabs of human autoantibodies in
[cited by applicant]
Miyazaki, “Studies on Alpaca VHH antibodies for industrial applications,” Kagoshima. University Repository, Jun. 1, 2015, 102 pages. https://ir.kagoshima-u.ac.jp/records/9025 (Machine translation provided).
[cited by applicant]
Smith-Gill et al., “Contributions of immunoglobulin heavy and light chains to antibody specificity for lysozyme and two haptens,” J. Immunol. (1987) 139:4135-44.
[cited by applicant]
Song et al., “Light chain of natural antibody plays a dominant role in protein antigen binding,” Biochem. Biophys. Res. Comm. (2000) 268:390-94.
[cited by applicant]
Ackerman et al., “Biologic activity in a fragment of recombinant human interferon alpha,” Proc Natl Acad Sci U S A. (1984) 81(4): 1045-1047.
[cited by applicant]
Al-Lazikani et al., “Standard Conformations for the Canonical Structures of Immunoglobulins,” J. Mol. Biol. (1997) 273: 927-948.
[cited by applicant]
Alegre et al., “Effect of a single amino acid mutation on the activating and immunosuppressive properties of a “humanized” OKT3 monoclonal antibody,” J Immunol (1992) 148(11):3461-3468.
[cited by applicant]
Almagro et al., “Humanization of Antibodies,” Frontiers in Bioscience. (2008) 13:1619-1633.
[cited by applicant]
Anasetti et al., “Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody,” Transplantation. (1992) 54(5): 844-51.
[cited by applicant]
Anderson et al., “Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells.,” Proc Natl Acad Sci USA. (1990) 87(6): 2274-2278.
[cited by applicant]
Arndt et al., “A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors,” Blood. (1999) 94(8): 2562-2568.
[cited by applicant]
Baca et al., “Antibody Humanization Using Monovalent Phage Display,” J. Biol. Chem. (1997) 272(16): 10678-10684.
[cited by applicant]
Bacac et al., “CD20 Tcb (RG6026), a Novel “2:1” T Cell Bispecific Antibody for the Treatment of B Cell Malignancies,” Blood (2016) 128:1836.
[cited by applicant]
Behar et al., “Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells,” Protein Eng Des Sel. (2008) 21(1): 1-10.
[cited by applicant]
Beliveau et al., “Probing the substrate specificities of matriptase, matriptase-2, hepsin and DESC1 with internally quenched fluorescent peptides,” FEBS J (2009) 276(8):2213-2226.
[cited by applicant]
Brinkmann et al., “The making of bispecific antibodies,” MABS (2017) 9(2):182-212.
[cited by applicant]
Bruggemann et al., “Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies,” J Exp Med (1987) 166(5):1351-1361.
[cited by applicant]
Capel et al., “Heterogeneity of Human IgG Fc Receptors,” Immunomethods (1994) 4(1): 25-34.
[cited by applicant]
Carsberg et al., “Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells,” Int J Cancer. (1996) 68(1): 84-92.
[cited by applicant]
Carter et al., “Bispecific human IgG by design,” J Immunol Methods (2001) 248(1-2):7-15.
[cited by applicant]
Carter et al., “Humanization of an Anti-p185HER2 Antibody For Human Cancer Therapy,” Proc. Natl. Acad. Sci. USA (1992) 89: 4285-4289.
[cited by applicant]
Chen et al., “Fusion protein linkers: property, design and functionality,” Adv Drug Deliv Rev (2013) 65(10):1357-1369.
[cited by applicant]
Clackson et al., “Making Antibody Fragments Using Phage Display Libraries,” Nature (1991) 352: 624-628.
[cited by applicant]
Clynes et al., “Fc receptors are required in passive and active immunity to melanoma,” Proc Natl Acad Sci USA (1998) 95(2):652-656.
[cited by applicant]
Cragg et al., “Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents,” Blood (2004) 103:2738-2743.
[cited by applicant]
Cragg et al., “Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts,” Blood (2003) 101(3):1045-1052.
[cited by applicant]
Daeron, “Fc receptor biology,” Annu Rev Immunol. (1997) 15: 203-34.
[cited by applicant]
Dall'Acqua et al., “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn),” J Biol Chem (2006) 281(33):23514-23524.
[cited by applicant]
Dall'Acqua et al., “Antibody Humanization by Framework Shuffling,” Methods (2005) 36:43-60.
[cited by applicant]
Davis et al., “SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies,” Protein Eng De…
[cited by applicant]
De Haas, M. et al. “Fc Gamma receptors of Phagocytes,” J. Lab. Clin. Med. (1995) 126:330-341.
[cited by applicant]
Deer et al., “High-Level Expression Of Proteins In Mammalian Cells Using Transcription Regulatory Sequences From The Chinese Hamster EF-1Alpha Gene,” Biotechnol. Prog. (2004) 20(3): 880-889.
[cited by applicant]
Deisenhofer, “Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from
[cited by applicant]
Diaz et al., “Structure of the human type-I interferon gene cluster determined from a YAC clone contig,” Genomics. (1994) 22(3): 540-552.
[cited by applicant]
Dotti et al., “Design and development of therapies using chimeric antigen receptor-expressing T cells,” Immunol Rev. (2014) 257(1); 35 pages.
[cited by applicant]
Endo et al., “High-Throughput, Genome-Scale Protein Production Method Based On The Wheat Germ Cell-Free Expression System,” Biotechnol. Adv. (2003) 21; 695-713.
[cited by applicant]
Gazzano-Santoro et al., “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody,” J Immunol Methods (1997) 202(2):163-171.
[cited by applicant]
Ghetie et al,. “FcRn: the MHC Class I-related Receptor That Is More Than An IgG Transporter,” Immunol. Today (1997) 18(12): 592-598.
[cited by applicant]
Ghetie et al., “Increasing the Serum Persistence of an IgG Fragment by Random Mutagenesis,” Nat Biotech (1997) 15:637-640.
[cited by applicant]
Golovleva et al., “Polymorphism in the interferon-alpha gene family,” Am J Hum Genet. (1996) 59(3): 570-8.
[cited by applicant]
Gunasekaran et al., “Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG,” J Biol Chem (2010) 285(25):19637-19646.
[cited by applicant]
Guyer et al., “Immunoglobulin binding by mouse intestinal epithelial cell receptors,” J Immunol. (1976) 117(2): 587-593.
[cited by applicant]
Ha et al., “Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins,” Front Immunol (2016) 7:394.
[cited by applicant]
Harwood et al., “ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy,” Oncoimmunology (2018) 7(1):e1377874.
[cited by applicant]
Hawkins et al., “Phase I evaluation of a synthetic mutant of beta-interferon,” Cancer Res. (1985) 45; 5914-20.
[cited by applicant]
Hayward et al., “Lysis of CD3 hybridoma targets by cloned human CD4 lymphocytes,” Immunology. (1988) 64(1): 87-92.
[cited by applicant]
Hellstrom et al., “Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas,” Proc Natl Acad Sci USA (1986) 83(18):7059-7063.
[cited by applicant]
Hellstrom et al., “Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside,” Proc Natl Acad Sci USA (1985) 82(5):1499-1502.
[cited by applicant]
Henry et al., “Stability-Diversity tradeoffs impose fundamental constraints on selection of synthetic human VH/VL single-domain antibodies from in vitro display libraries,” Frontiers in Immunology (2017) 8:1-15.
[cited by applicant]
Hernandez-Hoyos et al., “MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer,” Mol Cancer Ther (2016) 15(9):2155-2165.
[cited by applicant]
Hinman et al. “Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics,” Cancer Res. (1993) 53(14): 3336-3342.
[cited by applicant]
Hinton et al., “Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates,” J. Biol. Chem. (2004) 279(8): 6213-6216.
[cited by applicant]
Hole et al., “A 72 kD trophoblast glycoprotein defined by a monoclonal antibody,” Br J Cancer. (1988) 57(3): 239-246.
[cited by applicant]
Holliger et al., “Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody,” Protein Engineering Design and Selection (1996) 9(3):299-305.
[cited by applicant]
Honegger et al., “Yet Another Numbering Scheme for Immunoglobulin Variable Domains: An Automatic Modeling and Analysis Tool,” J Mol Biol. (2001) 309(3): 657-670.
[cited by applicant]
Hussain et al., “IFN-alpha1a gene is the major variant in the North American population,” J Interferon Cytokine Res. (2000) 20(9): 763-768.
[cited by applicant]
Idusogie et al., “Engineered antibodies with increased activity to recruit complement,” J Immunol (2001) 166(4):2571-2575.
[cited by applicant]
Jaitin et al., “Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta,” Mol Cell Biol. (2006) 26(5): 1888-1897.
[cited by applicant]
Jendeberg et al., “Engineering of Fc(1) and Fc(3) from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A,” J Immnuol Methods (1997) 201(1):25-34.
[cited by applicant]
Jones et al., “Investigation of expression of 5T4 antigen in cervical cancer,” Br J Cancer. (1990) 61(1): 96-100.
[cited by applicant]
Kalie et al., “An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities,” J Biol Chem. (2007) 282(15): 11602-11611.
[cited by applicant]
Kaneko et al., “Optimizing Therapeutic Antibody Function,” Biodrugs (2011) 25(1):1-11.
[cited by applicant]
Kashmiri et al., “SDR grafting—A New Approach to Antibody Humanization,” Methods. (2005) 36: 25-34.
[cited by applicant]
Kerk et al., “5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma,” Clin Cancer Res. (2017) 23(10): 2516-2527.
[cited by applicant]
Kim et al., “Mutational approaches to improve the biophysical properties of human single-domain antibodies,” Biochimica et Biophysica Acta (2014) 1844:1983-2001.
[cited by applicant]
Kim et al., “Localization of the Site of the Murine IgGI Molecule That is Involved in Binding to the Murine Intestinal Fc Receptor,” Eur. J. Immunol. (1994) 24:2429-2434.
[cited by applicant]
Kindt, T.J .et al. (2007). “Antigens And Antibodies,” Chapter 4 In Kuby Immunology 6th Ed., W.H. Freeman And Co., p. 91.
[cited by applicant]
Kipriyanov et al., “Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics,” J Mol Biol (1999) 293(1):41-56.
[cited by applicant]
Klimka et al., “Human Anti-CD30 Recombinant Antibodies by Guided Phage Antibody Selection Using Cell Panning,” Br. J. Cancer (2000) 83(2):252-260.
[cited by applicant]
Kohler et al., “Continuous Culture of Fused Cells Secreting Antibody of Predefined Specificity,” Nature (1975) 256:495-497.
[cited by applicant]
Krause et al., “Signaling by covalent heterodimers of interferon-gamma. Evidence for one-sided signaling in the active tetrameric receptor complex,” J Biol Chem. (2000) 275(30); 22995-3004.
[cited by applicant]
La Rocca et al., “Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera,” British Journal of Cancer (2004) 90:1414-1421.
[cited by applicant]
Lazar et al., “Engineered antibody Fc variants with enhanced effector function,” Proc Natl Acad Sci USA (2006) 103(11):4005-4010.
[cited by applicant]
Leaver-Fay et al., “Computationally Designed Bispecific Antibodies using Negative State Repertoires,” Structure (2016) 24(4):641-651.
[cited by applicant]
Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol (2003) 27(1):55-77.
[cited by applicant]
Liu et al., “Eradication of Large Colon Tumor Xenografts by Targeted Delivery of Maytansinoids,” Proc. Natl. Acad. Sci. USA (1996) 93: 8618-8623.
[cited by applicant]
Lode et al., “Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma,” Cancer Res. (19…
[cited by applicant]
MacCallum et al., “Antibody-antigen interactions: Contact analysis and binding site topography,” J. Mol. Biol. (1996) 262, 732-745.
[cited by applicant]
Mandler et al., “Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin immunoconjugate,” Bioorg Med Chem Lett. (2000) 10(10): 1025-1028.
[cited by applicant]
Mandler et al., “Modifications in Synthesis Strategy Improve the Yield and Efficacy of Geldanamycin-Herceptin Immunoconjugates,” Bioconjugate Chem. (2002)13:786-791.
[cited by applicant]
Mandler et al., “Immunoconjugates of Geldanan1ycin and Anti-HER2 Monoclonal Antibodies: Antiproliferative Activity on Human Breast Carcinoma Cell Lines,” J. Nat. Cancer Inst. (2000) 92(19): 1573-1581.
[cited by applicant]
Martin et al., “Modeling antibody hypervariable loops: a combined algorithm,” Proc Natl Acad Sci U S A. (1989) 86(23): 9268-9272.
[cited by applicant]
McCafferty et al., “Phage antibodies: filamentous phage displaying antibody variable domains,” Nature (1990) 348:552-554.
[cited by applicant]
McGinn et al., “Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia,” Haematologica. (2017) 102(6): 1…
[cited by applicant]
Merchant et al., “An efficient route to human bispecific IgG,” Nat Biotechnol (1998) 16(7):677-681.
[cited by applicant]
Miller, “Protein-protein recognition and the association of immunoglobulin constant domains,” JMB (1990) 216(4):965-973.
[cited by applicant]
Moore et al., “A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens,” MAbs (2011) 3(6):546-557.
[cited by applicant]
Moore et al., “Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions,” MAbs (2010) 2(2):181-189.
[cited by applicant]
Nagorsen et al., “Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab,” Exp Cell Res. (2011) 317(9): 1255-60.
[cited by applicant]
Natsume et al., “Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities,” Cancer Res (2008) 68(10):3863-3872.
[cited by applicant]
Nyman et al., “Structural characterisation of N-linked and O-linked oligosaccharides derived from interferon-alpha2b and interferon-alpha14c produced by Sendai-virus-induced human peripheral blood leukocytes,” Eur J Bio…
[cited by applicant]
Ohannesian et al., “Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells,” Cancer Res. (1995) 55(10): 2191-2199.
[cited by applicant]
Osbourn, et al., “From Rodent Regents to Human Therapeutics Using Antibody Guided Selection,” Methods. (2005) 36:61-68.
[cited by applicant]
Padlan, “A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties,” Mol Immunol (1991) 28(4-5):489-498.
[cited by applicant]
Pan et al., “Structural characterization of human interferon gamma. Heterogeneity of the carboxyl terminus,” Eur J Biochem. (1987) 166(1): 145-149.
[cited by applicant]
Pan et al., “Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy,” Int J Nanomedicine. (2018)13: 3189-3201.
[cited by applicant]
Pessano, S. et al., “The T3/T Cell Receptor Complex: Antigenic Distinction Between The Two 20-kd T3 (T3-δand T3-ϵ) Subunits,” The EMBO Journal (1985) 4(2):337-344.
[cited by applicant]
Petkova et al., “Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease,” Int Immunol (2006) 18(12):1759-1769.
[cited by applicant]
Pollard et al., “Fixation, processing, and immunochemical reagent effects on preservation of T-lymphocyte surface membrane antigens in paraffin-embedded tissue,” J Histochem Cytochem. (1987)35(11): 1329-38.
[cited by applicant]
Portolano et al., “Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by human H and L chain “roulette”,” J. Immunol. (1993) 150:880-887.
[cited by applicant]
Presta et al., “Humanization of an Antibody Directed Against IgE,” J. Immunol. (1993) 151(2): 2623-2632.
[cited by applicant]
Queen et al., “A humanized antibody that binds to the interleukin 2 receptor,” Proc Natl Acad Sci USA (1989) 86:10029-10033.
[cited by applicant]
Ravetch et al., “Fc receptors,” Annu Rev Immunol. (1991) 9:457-92.
[cited by applicant]
Reusch et al., “A Novel Tetravalent Bispecific T and Ab (CD30/CD 16A) Efficiently Recruits NK Cells For The Lysis Of CD30+ Tumor Cells,” mABs (2014) 6(SUPPL 3): 727-738.
[cited by applicant]
Ridgway et al., “‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization,” Protein engineering (1996) 9(7):617-621.
[cited by applicant]
Riechmann et al., “Reshaping Human Antibodies for Therapy,” Nature (1988) 332: 323-327.
[cited by applicant]
Rosenberg et al., “Use Of Tumor-Infiltrating Lymphocytes And Interleukin-2 In The Immunotherapy Of Patients With Metastatic Melanoma. A Preliminary Report,” N Engl J Med. (1988) 319(25): 1676-1680.
[cited by applicant]
Rosok et al., “A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab,” J. Biol. Chem. (1996) 271(37): 22611-22618.
[cited by applicant]
Rowland et al., “Drug Localisation And Growth Inhibition Studies of Vindesine-Monoclonal Anti-CEA Conjugates in a Human Tumour Xenograft,” Cancer Immunol. Immunother. (1996) 21:183-187.
[cited by applicant]
Sadelain et al., “The basic principles of chimeric antigen receptor design,” Cancer Discov. (2013) 3(4): 388-398.
[cited by applicant]
Sadelain et al., “The promise and potential pitfalls of chimeric antigen receptors,” Curr Opin Immunol. (2009) 21(2): 215-23.
[cited by applicant]
Seimetz et al., “Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy,” Cancer Treat Rev (2010) 36:458-467.
[cited by applicant]
Shields et al., “High Resolution Mapping of the Binding Site on Human IgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR*,” JBC (2001) 276(9):6591-6604.
[cited by applicant]
Sims et al., “A Humanized CD18 Antibody Can Block Function Without Cell Destruction,” J. Immunol. (1993) 151(4): 2296-2308.
[cited by applicant]
Sitaraman et al., “High-throughput protein expression using cell-free system,” Methods Mol. Biol. (2009) 498: 229-44.
[cited by applicant]
Southall et al., “Immunohistological distribution of 5T4 antigen in normal and malignant tissues,” Br J Cancer. (1990) 61(1): 89-95.
[cited by applicant]
Southgate et al., “CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells,” PLoS One. (2010) 5(4): e9982.
[cited by applicant]
Spirin, “High-Throughput Cell-Free Systems For Synthesis Of Functionally Active Proteins,” Trends Biotechnol. (2004) 22(10): 538-545.
[cited by applicant]
Starzynska et al., “The expression of 5T4 antigen in colorectal and gastric carcinoma,” Br J Cancer. (1992) 66(5): 867-869.
[cited by applicant]
Stavenhagen et al., “Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization,” Adv Enzyme Regul (2008) 48:152-164.
[cited by applicant]
Stavenhagen et al., “Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fcγ Receptors,” Cancer Res (2007) 67(18…
[cited by applicant]
Taylor et al., “Nanocell targeting using engineered bispecific antibodies,” mAbs (2015) 7(1):53-65.
[cited by applicant]
Uhlmann et al., “Antisense oligonucleotides: a new therapeutic principle,” Chem Rev (1990) 90(4):543-584.
[cited by applicant]
Von Kreudenstein et al., “Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design,” MAbs (2013) 5(5):646-654.
[cited by applicant]
Wang, “Lyophilization and development of solid protein pharmaceuticals,” Int J Pharm (2000) 203(1-2):1-60.
[cited by applicant]
Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from
[cited by applicant]
Wirthmueller et al., “Signal transduction by Fc gamma RIII (CD16) is mediated through the gamma chain,” J Exp Med. (1992) 175(5):1381-90.
[cited by applicant]
Yang et al., “A Common Pathway For T Lymphocyte Activation Involving Both The CD3-Ti Complex And CD2 Sheep Erythrocyte Receptor Determinants,” J. Immunol. (1986) 137(4): 1097-1100.
[cited by applicant]
Young et al., “Antibody-Cytokine Fusion Proteins For Treatment Of Cancer: Engineering Cytokines For Improved Efficacy and Safety,” Seminars In Oncology. (2014) 41(5):623-636, 19 pages.
[cited by applicant]
Zalevsky et al., “Enhanced antibody half-life improves in vivo activity,” Nat Biotechnol (2010) 28(2):157-159.
[cited by applicant]
Golovleva et al., “Ethnic differences in interferon-alpha allele frequencies,” Hum Hered. (1997) 47(4): 185-188.
[cited by applicant]
Golovleva et al., “Novel variants of human IFN-alpha detected in tumor cell lines and biopsy specimens,” J Interferon Cytokine Res. (1997) 17(10): 637-645.
[cited by applicant]
Hussain et al., “Interferon-alpha 8b is the only variant of interferon-alpha 8 identified in a large human population,” J Interferon Cytokine Res. (1996) 16(7): 523-529.
[cited by applicant]
Hussain et al., “Both variant forms of interferon-alpha4 gene (IFNA4a and IFNA4b) are present in the human population,” J Interferon Cytokine Res. (1997) 17(9): 559-566.
[cited by applicant]
Hussain et al., “A new allele of interferon-alpha17 gene encoding IFN-alpha17b is the major variant in human population,” J Interferon Cytokine Res. (1998) 18(7): 469-77.
[cited by applicant]
Kim et al., “Interferon, alpha 17 (IFNA17) IIe184Arg polymorphism and cervical cancer risk,” Cancer Lett. (2003) 189(2); 183-188.
[cited by applicant]
Kita et al., “Determination of interferon-alpha2 allele composition in the genomic DNA from healthy volunteers and leukemic patients in Japan,” J Interferon Cytokine Res. (1997) 17(3); 135-140.
[cited by applicant]
Ledbetter et al., “Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and pr…
[cited by applicant]
Linge et al., “Transcription of interferon-alpha 2 alleles from virus-induced human leucocytes and lymphoblastoid cells of African origin,” Biochim Biophys Acta. (1995) 1264(3):363-8.
[cited by applicant]
Lundell et al., “The carboxyl-terminal region of human interferon gamma is important for biological activity: mutagenic and NMR analysis,” Protein Eng. (1991) 4(3): 335-341.
[cited by applicant]
McCall et al., “Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis,” Mol. Immunol. (1999) …
[cited by applicant]
Nicolaou et al., “Calicheamicin θ: A Rationally Designed Molecule with Extremely Potent and Selective DNA Cleaving Properties and Apoptosis Inducing Activity,” Angew Chem Int Edit (1994) 33(2):183-186.
[cited by applicant]
Pestka et al., The human interferons—from protein purification and sequence to cloning and expression in bacteria: before, between, and beyond, Arch Biochem Biophys. (1983) 221(1): 1-37.
[cited by applicant]
Pestka, vol. 119. Interferons (Part C) (1986) Meth. Enzymol, 199: 3-4.
[cited by applicant]
Rodrigues et al., “Engineering a humanized bispecific F(ab′)2 fragment for improved binding to T cells,” Int J Cancer Suppl. (1992) 7:45-50.
[cited by applicant]
Starzynska et al., “5T4 oncofetal antigen in gastric carcinoma and its clinical significance,” Eur J Gastroenterol Hepatol. (1998) 10(6): 479-484.
[cited by applicant]
Valedkarimi et al., “Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy,” Biomed Pharmacother. (2017) 95: 731-742.
[cited by applicant]
Van De Winkel et al., “Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications,” Immunol Today. (1993) 14(5): 215-21.
[cited by applicant]
Wrigley et al., “5T4 oncofetal antigen expression in ovarian carcinoma.,” Int J Gynecol Cancer. (1995) 5(4): 269-274.
[cited by applicant]
Yamamoto et al., “Creation of interferon-alpha8 mutants with amino acid substitutions against interferon-alpha receptor-2 binding sites using phage display system and evaluation of their biologic properties,” J Interfer…
[cited by applicant]